Medshine Discovery Inc.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Guangdong Raynovent Biotech Co., Ltd.

Other

Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd.

Cspc Zhongqi Pharmaceutical Technology (shijiazhuang) Co., Ltd.

Shandong Danhong Pharmaceutical Co., Ltd.

Qilu Pharmaceutical Co., Ltd.

Sichuan University

Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Yangtze River Pharmaceutical Group Co., Ltd.

Shandong Luye Pharmaceutical Co., Ltd.

Shanghai Haiyan Pharmaceutical Technology Co., Ltd.

Jiangsu Kanion Pharmaceutical Co., Ltd.

Nanjing Sanhome Pharmaceutical Co., Ltd.

Shuhui Chen

Jian Li

Charles Z Ding

Guoping Hu

Haiying He

Lingyun Wu

Lihong Hu

Wenyuan Qian

Peng Li

Chengde Wu

Jie Li

Kevin X Chen

Chaofeng Long

Xiaoxin Chen

Zhengxia Chen

Tao Yu

Wentao Wu

Jianfei Wang

Fang Liu

Yunfu Luo

Zhigan Jiang

Zhi Luo

Chundao Yang

Hao Wu

Fei Sun

Zhen Gong

Zhuowei Liu

Peng Zhang

Yong Wang

Jian Xiong

Xiaolin Li

Bin Chen

Zhaozhong Ding

Fei Wang

Kai Zhou

Zheng Wang

Yuan Chen

Xiquan Zhang

Xuanjia Peng

Weidong Li

Chen Zhang

Xing Liu

Lei Zhang

Wei Luo

Cheng Li

Ling Yang

Tie-Lin Wang

Yuquan Wei

Yong Xu

Lie Li

Ning Li

Shilan Liu

Weihua Shi

Jian Wang

Wei Huang

Wei Wang

Xiao Xun Zhang

Jing Wang

Cong Wang

Hui Liu

Hongwei Li

Jun Yin

Feng Gao

Hongjiang Xu

Tao Feng

Jing Zhang

Zhiqiang Liu

Jun Lin

Dahai Wang

Bo Gao

Ting Wang

Yan Wang

Yong Liang Liu

Ming Zhang

Yi Bu Li

Bin Liu

Yi Chen

Yang Zhang

Jiong Lan

Lu Zhang

Chun Sing Li

Feng Guo

Wei Wei

Wei Gu

Kun Peng Wang

Jun Yu

Wei Xiao

Rui Zhao

Xin Tian

Ling Liu

Jun Zhao

Xiao Liu

Jie Gandalf Yan

Long Zhang

Hui Zhou

Xu Zeng

Disclosed are a class of compounds having a highly selective inhibition of ROS1, and the use thereof in the preparation of drugs for treating diseases related to abnormal ROS1 kinase expression. Specifically disclosed are compounds represented by formula (IV) and a pharmaceutically acceptable salt thereof.

Compound as highly selective ROS1 inhibitor and use thereof

An aminopyridine compound, which is specifically a compound represented by formula (P), and a pharmaceutically acceptable salt thereof. The compound can be used to prepare drugs for treating deep fungal infections.

Aminopyridine compound and application thereof

Disclosed are pyrrolotriazine compounds which act as a mitogen-activated protein kinase interacting kinase (MNK) inhibitor, and the use thereof in the preparation of a mitogen-activated protein kinase interacting kinase inhibitor drug. Specifically disclosed are compounds represented by formula (I) or a pharmaceutically acceptable salt thereof.

Pyrrolotriazine compounds acting as MNK inhibitor

The present invention discloses the crystal forms as a JAK inhibitor and their application in the preparation of drugs for the treatment of JAK1 or/and TYK2 related diseases.

Crystalline form of JAK inhibitor and application thereof

Disclosed are an acetophenone oxime compound and a preparation method therefor, and specifically disclosed are a compound as shown in formula (II) and a pharmaceutically acceptable salt thereof.

Acetophenone oxime compound and application thereof

Provided is an aldehyde binder, specifically, disclosed is a compound as represented by formula (II) or a pharmaceutically acceptable salt.

Compound for use in retinal diseases

Crystalline forms of an ATR inhibitor, preparation methods therefor, and the use thereof in the preparation of a drug for treating ATR-related diseases. In particular, crystalline forms of an ATR inhibitor represented by formula (I), physicochemical and biochemical properties of the same, preparation methods for, and uses of the same, in the preparation of a drug for treating ATR-related diseases.

Crystalline form of ATR inhibitor and use thereof

The use of a phenylpropionamide compound in the preparation of a drug for treating diseases associated with pain and pruritus. Specifically, the present invention relates to a compound as represented by formula (I) or a pharmaceutically acceptable salt thereof.

Phenylpropionamide compound and use thereof

A crystal form of a pyridinylphenyl compound and a preparation method therefor. Use of the crystal form in the preparation of a medicament of treating related diseases is also comprised.

Crystal form of pyridinylphenyl compound and preparation method therefor

Disclosed are a series of compounds having pyridine structures or pharmaceutically acceptable salts thereof, and an application thereof in the preparation of drugs for the treatment of related diseases. Specifically, disclosed is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.

Pyridine derivative and application thereof

The present disclosure discloses a class of macrocyclic derivatives, and specifically discloses a compound shown in formula (VI), a stereoisomer thereof, and a pharmaceutically acceptable salt thereof.

Macrocyclic derivative and use thereof

Provided are a class of multi-targeted inhibitors of IRAK4 and BTK, and the use thereof in preparing a drug for treating IRAK4- and BTK-related diseases. The present invention specifically relates to the compounds represented by formula (II), isomers thereof or pharmaceutically acceptable salts thereof.

Oxazole compound as multi-targeted inhibitor of IRAK4 and BTK

Disclosed is a fluoropyrrolopyridine compound, and specifically disclosed is a compound represented by formula (II), an isomer or a pharmaceutically acceptable salt thereof.

Fluoropyrrolopyridine compound and application thereof

Provided is an isochroman compound represented by formula (I), or a pharmaceutically acceptable salt thereof, which is used as an aldo-keto reductase (AKR1C3) inhibitor for the treatment of liver cancer.

Isochroman compound

Disclosed in the present invention is a series of dimethylsulfoximine derivatives, and specifically disclosed are a compound represented by formula (II) and a pharmaceutically acceptable salt thereof.

Dimethylsulfoximine derivative

Growing community of inventors

Shanghai, China

Shuhui Chen